137 related articles for article (PubMed ID: 31511935)
21. Differences in cytochrome p450-mediated pharmacokinetics between chinese and caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling.
Barter ZE; Tucker GT; Rowland-Yeo K
Clin Pharmacokinet; 2013 Dec; 52(12):1085-100. PubMed ID: 23818090
[TBL] [Abstract][Full Text] [Related]
22. Prediction of dose-dependent in vivo acetylcholinesterase inhibition by profenofos in rats and humans using physiologically based kinetic (PBK) modeling-facilitated reverse dosimetry.
Omwenga I; Zhao S; Kanja L; Mol H; Rietjens IMCM; Louisse J
Arch Toxicol; 2021 Apr; 95(4):1287-1301. PubMed ID: 33651127
[TBL] [Abstract][Full Text] [Related]
23. Species-Specific Differences in the in Vitro Metabolism of Lasiocarpine.
Fashe MM; Juvonen RO; Petsalo A; Räsänen J; Pasanen M
Chem Res Toxicol; 2015 Oct; 28(10):2034-44. PubMed ID: 26395423
[TBL] [Abstract][Full Text] [Related]
24. The Role of Kinetics as Key Determinant in Toxicity of Pyrrolizidine Alkaloids and Their N-Oxides.
Widjaja F; Alhejji Y; Rietjens IMCM
Planta Med; 2022 Feb; 88(2):130-143. PubMed ID: 34741297
[TBL] [Abstract][Full Text] [Related]
25. Effects of glutathione and cysteine on pyrrolizidine alkaloid-induced hepatotoxicity and DNA adduct formation in rat primary hepatocytes.
He X; Xia Q; Shi Q; Fu PP
J Environ Sci Health C Toxicol Carcinog; 2020; 38(2):109-123. PubMed ID: 32500832
[TBL] [Abstract][Full Text] [Related]
26. Pyrrolizidine alkaloid-derived DNA adducts as a common biological biomarker of pyrrolizidine alkaloid-induced tumorigenicity.
Xia Q; Zhao Y; Von Tungeln LS; Doerge DR; Lin G; Cai L; Fu PP
Chem Res Toxicol; 2013 Sep; 26(9):1384-96. PubMed ID: 23937665
[TBL] [Abstract][Full Text] [Related]
27. Predicting points of departure for risk assessment based on in vitro cytotoxicity data and physiologically based kinetic (PBK) modeling: The case of kidney toxicity induced by aristolochic acid I.
Abdullah R; Alhusainy W; Woutersen J; Rietjens IM; Punt A
Food Chem Toxicol; 2016 Jun; 92():104-16. PubMed ID: 27016491
[TBL] [Abstract][Full Text] [Related]
28. In vitro biotransformation of pyrrolizidine alkaloids in different species: part II-identification and quantitative assessment of the metabolite profile of six structurally different pyrrolizidine alkaloids.
Geburek I; Schrenk D; These A
Arch Toxicol; 2020 Nov; 94(11):3759-3774. PubMed ID: 32880719
[TBL] [Abstract][Full Text] [Related]
29. 7-Glutathione-pyrrole and 7-cysteine-pyrrole are potential carcinogenic metabolites of pyrrolizidine alkaloids.
He X; Xia Q; Fu PP
J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2017 Apr; 35(2):69-83. PubMed ID: 28418776
[TBL] [Abstract][Full Text] [Related]
30. Human liver microsomal metabolism and DNA adduct formation of the tumorigenic pyrrolizidine alkaloid, riddelliine.
Xia Q; Chou MW; Kadlubar FF; Chan PC; Fu PP
Chem Res Toxicol; 2003 Jan; 16(1):66-73. PubMed ID: 12693032
[TBL] [Abstract][Full Text] [Related]
31. Integrating in vitro data and physiologically based kinetic modeling-facilitated reverse dosimetry to predict human cardiotoxicity of methadone.
Shi M; Bouwmeester H; Rietjens IMCM; Strikwold M
Arch Toxicol; 2020 Aug; 94(8):2809-2827. PubMed ID: 32367273
[TBL] [Abstract][Full Text] [Related]
32. Metabolic activation of retronecine and retronecine N-oxide - formation of DHP-derived DNA adducts.
Yan J; Xia Q; Chou MW; Fu PP
Toxicol Ind Health; 2008 Apr; 24(3):181-8. PubMed ID: 18842697
[TBL] [Abstract][Full Text] [Related]
33. Letter to the Editor : Comment on 'Use of an in vitro-in silico testing strategy to predict inter-species and inter-ethnic human differences in liver toxicity of the pyrrolizidine alkaloids lasiocarpine and riddelliine' by Ning et al., Arch Toxicol doi: https://doi.org/10.1007/s00204-019-02397-7.
Mielke H; Partosch F; Gundert-Remy U
Arch Toxicol; 2019 May; 93(5):1465-1466. PubMed ID: 31076803
[No Abstract] [Full Text] [Related]
34. 7-glutathione pyrrole adduct: a potential DNA reactive metabolite of pyrrolizidine alkaloids.
Xia Q; Ma L; He X; Cai L; Fu PP
Chem Res Toxicol; 2015 Apr; 28(4):615-20. PubMed ID: 25768656
[TBL] [Abstract][Full Text] [Related]
35. Physiologically based kinetic modeling of senecionine N-oxide in rats as a new approach methodology to define the effects of dose and endpoint used on relative potency values of pyrrolizidine alkaloid N-oxides.
Widjaja F; Zheng L; Wesseling S; Rietjens IMCM
Front Pharmacol; 2023; 14():1125146. PubMed ID: 36937884
[TBL] [Abstract][Full Text] [Related]
36. The roles of CYP3A and CYP2B isoforms in hepatic bioactivation and detoxification of the pyrrolizidine alkaloid senecionine in sheep and hamsters.
Huan JY; Miranda CL; Buhler DR; Cheeke PR
Toxicol Appl Pharmacol; 1998 Aug; 151(2):229-35. PubMed ID: 9707499
[TBL] [Abstract][Full Text] [Related]
37. Human CYP3A4-mediated toxification of the pyrrolizidine alkaloid lasiocarpine.
Ebmeyer J; Braeuning A; Glatt H; These A; Hessel-Pras S; Lampen A
Food Chem Toxicol; 2019 Aug; 130():79-88. PubMed ID: 31103741
[TBL] [Abstract][Full Text] [Related]
38. Next generation risk assessment (NGRA): Bridging in vitro points-of-departure to human safety assessment using physiologically-based kinetic (PBK) modelling - A case study of doxorubicin with dose metrics considerations.
Li H; Yuan H; Middleton A; Li J; Nicol B; Carmichael P; Guo J; Peng S; Zhang Q
Toxicol In Vitro; 2021 Aug; 74():105171. PubMed ID: 33848589
[TBL] [Abstract][Full Text] [Related]
39. New glutathione conjugate of pyrrolizidine alkaloids produced by human cytosolic enzyme-dependent reactions in vitro.
Muluneh F; Häkkinen MR; El-Dairi R; Pasanen M; Juvonen RO
Rapid Commun Mass Spectrom; 2018 Aug; 32(16):1344-1352. PubMed ID: 29788543
[TBL] [Abstract][Full Text] [Related]
40. In silico prediction of the site of oxidation by cytochrome P450 3A4 that leads to the formation of the toxic metabolites of pyrrolizidine alkaloids.
Fashe MM; Juvonen RO; Petsalo A; Vepsäläinen J; Pasanen M; Rahnasto-Rilla M
Chem Res Toxicol; 2015 Apr; 28(4):702-10. PubMed ID: 25651456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
